Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Therapy Area Hub

Cardiology / Cardiovascular

Cardiovascular guidance, trial updates, drug mechanisms and CPD resources for clinicians following rapidly changing prevention, heart failure and cardiometabolic evidence.

26 Guidelines 317 Trials 27 News 5 Mechanisms
Clinical Intelligence

Latest Guidelines

View all 26
05 Aug 2026

Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction

Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can be initiated in primary or secondary…

Independent Editorial Public / open access
30 Jul 2026

Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy

Patient selection: Consider aficamten for symptomatic obstructive hypertrophic cardiomyopathy patients who remain symptomatic despite optimised standard therapy (beta-blockers, non-dihydropyridine calcium channel blockers, or disopyramide), or who…

Independent Editorial Public / open access
16 Jul 2026

Netarsudil for treating open-angle glaucoma or ocular hypertension (terminated evaluation)

Netarsudil evaluation by NICE was terminated, indicating it is not recommended for routine use in NHS treatment pathways for open-angle glaucoma or ocular hypertension—continue using established…

Independent Editorial Public / open access
03 Jun 2026

Sotatercept for treating pulmonary arterial hypertension

Sotatercept is recommended as a treatment option for pulmonary arterial hypertension (PAH) in patients who meet NICE criteria; verify patient eligibility and existing PAH therapy status…

Independent Editorial Public / open access
19 May 2026

Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment

AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving clinical workflow efficiency in…

Independent Editorial Public / open access
07 May 2026

Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity

Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part of a comprehensive cardiovascular…

Independent Editorial Public / open access
Research

Trial Radar

View all 317
What Changed

Clinical News

View all 27
Drug Science

Relevant Mechanisms

Open library
Education

CPD, Podcasts & Webinars

Education hub
Stay Updated

Follow Cardiology / Cardiovascular safety updates

Get MHRA safety alerts and clinically relevant updates for this specialty in your ClinicaliQ digest.

Set Safety Preferences →
Stay Updated

Follow Cardiology / Cardiovascular

Choose guideline, trial, Drug Science and education updates for this specialty.

Set Specialty Preferences →